We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
- |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | O | 0 | 27.30 | GBX |
Diurnal (DNL) Share Charts1 Year Diurnal Chart |
|
1 Month Diurnal Chart |
Intraday Diurnal Chart |
Date | Time | Title | Posts |
---|---|---|---|
11/11/2022 | 09:16 | Diurnal Group plc | 5,459 |
04/8/2020 | 06:08 | Diurnal (MC Ј25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP | 404 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 31/8/2022 18:50 by best1467 Spruce is the main candidate but as considerable cash burn.$100 million in cash and the share price at multi year lows it’s possibly to risky a proposition They could possibly trump the current bid say around 35p which should leave sufficient cash to fund the current cash burn for the combined group until YE2023. It will be extremely disappointing if the current deal completes but not a total surprise |
Posted at 31/8/2022 07:52 by jaspoland If the market thought a counter bid was in the offing the share price would be nearer or over 27.5p let's see where the price goes today. I'd say it's a done deal unless someone comes along with something nearer 50p |
Posted at 30/8/2022 08:43 by deanmatlazin Should be a counter bid. Too cheap at this price to be honest. no competitor and whoever bought DNL will make loads of money in coming years. I agree it should be taken over about £100m.There was an article about British companies were being bought at cheap price with current economic climate. What a shame! |
Posted at 30/8/2022 07:15 by aimmafia If you havent looked at #CGO then you really should, 200-300 percent upside very near termCurrent Share Price: 7.5pTarget Share Price: 30p in Q4 when 2nd offtake agreement lands and we are earning $10million a year from 1st offtake.Offtake 1: 10,000 tonnes per month of washed coking coalSale Price: $120 Per TonneRevenue: $14.4 MillionEBITDA: $9.6 MillionReserves: 1.6 Billion tonnes Met Coal / Thermal Coal ( company can run for centuries )Offtake 2: in discussionAlso CGO has its Initial Modular coke Battery due to be installed in Q4 which will create even more revenue and expecting another offtake agreement to land for this also! Production will be up to 40,000 tonnes per year of raw coke with huge margins creating the below figures but I am expecting coke prices to go up even further.Modular coke battery will produce once installedMargin: $300 per tonneEbitda 2022 with module coke battery- $19.5 millionPE of 5: $100m Market Cap aprxPE of 7: $140m Market Cap aprxIn 2023 a further large battery will be installed and adding a further $45million Ebitda per year creating rough market caps of:PE5 $285 million Market Cap 2023PE7 $399 million Market Cap 2023This is obviously excluding value of gold asset and also hugely increased coking coal and coke prices. |
Posted at 15/8/2022 08:46 by rgmgo Weatherman. You can also cross reference with the Diurnal sales commentary, unfortunately, and deliberately, I don't think you have quite enough disclosure to be definitive on the numbers. I have some guestimates for US alkindi sales which are half yearly rather than quarterly. 1H2022 $1.0mn, 2H2022 $1.5mn , 2022E $2.5mn(out of underlying group sales of $2.8mn), 2023E $8mn. Why the big jump in 2023? Well we know the sequential growth numbers are high and sales only really picked up momentum in 4Q2022 with the game changing Tolmar distribution deal. We also know that alkindi is Eton's biggest product so these numbers are not inconsistent with already reported $4.5mn product sales and royalties revenues for 1H2022 and the $15mn 2023E revenue commentary (they have already booked $5mn royalty licensing revenues so I am guestimating c $10mn Eton product sales. That said, please feel free to unpick the logic, iterate some different numbers. If however these expectations are close to being right, the message is a strong one. 1. The numbers are beginning to get material in the US, 2. DNL could be closing in on the next sales milestone payment (they receive $1mn from Eton when net sales exceed $100 million in a calendar year). We know from a recent Eton call that the Tolmar sales force is going through a reorganisation which may adversely impact shorter term sales but is expected to steepen longer term growth, so this will likely push the $10mn revenue milestone into calendar 2024. It is also worth reiterating that DNL only receives a tiered royalty from Eton ranging from a low double-digit to high teens percentage on net sales of Alkindi Sprinkle, so the impact is muted on the DNL reported revenues. However, if momentum is maintained there are some chunky milestones down the line, $4 million when net sales exceed $25 million in a calendar year, $7.5 million when net sales exceed $50 million in a calendar year etc. Eton believes alkindi has $100mn+ US sales potential. Alkindi US is only one part of the DNL growth story but it might provide some much needed validation of the model. If DNL can successfully negotiate the nearer term funding gap without too much dilution, long suffering shareholders may eventually get some reward. |
Posted at 12/8/2022 19:19 by bamboo2 At that kind of figure, the share price here would be around 55-60pMight have to get a few more! |
Posted at 12/8/2022 15:02 by bamboo2 Any long termers, if my maths is correct, market cap at 12p share price is just £20.4mWould Eton think about making an offer? They have a substantial cash pile. |
Posted at 12/8/2022 11:23 by deanmatlazin Open Offerand Notice of General Meeting Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, is pleased to announce the completion of the Bookbuild announced earlier today, which was oversubscribed. A total of 28,507,144 Placing Shares have been conditionally placed at the Issue Price of 70 pence per New Ordinary Share alongside a conditional subscription by certain Directors of the Company for 64,285 Subscription Shares, also at the Issue Price, to raise a total of approximately GBP 20.0 million for the Company (before expenses). From April 2021 - Placing 70p/share. Long way for them to recoup the losses. I hope this will come good soon. Nice recovery play |
Posted at 28/7/2022 08:37 by aimmafia Tburns. Seeing as the share price is doing so well, I suspect the directors will be awarded more shares for current shareprice performance |
Posted at 05/4/2022 07:58 by wololol For existing investors the share price has killed all sentiment. As a new investor I can't see why the WPhas droped so much. They have growing revenues , several assets at late stage development and a bug chunk of cash in the bank. The previous fund raises were not significantly discounted and they have stated next funding may not be dilutive. I don't expect them to raise money within a year and by that point the share price should be much higher. Therefore i am building a position pretty much at all time lows with so much news flow due this year. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions